If yu ɔr pɔrsin wae yu lɛk gɛt bɔdi kansa, yu go mɔs dɔn yɛri di wɔd ‘immunotherapy’ we dɛn kin trowe wae i kam pan tritmɛnt. Yu dɔktɔ go dɔn ivin tɔk bɔt am. So, wetin na dis nyu tritmɛnt fɔ bɔku pipul dɛn? Yu tink se i go rili ebul fɔ fɛt kansa? Lɛ wi tɔk bɔt am simpul wan we yu go ɔndastand.
So, wetin na Immunotherapy?
Fɔ tɔk am simpul wan, imyunotɛrapi na tritmɛnt we de yuz yu bɔdi in yon sik-fayt sistɛm (di imyun sistɛm) fɔ ɛp fɔ fɛn ɛn pwɛl kansa sɛl dɛn. i tan lεk fכ tren yu bכdi in כwn "ami" fכ no εn atak "εnεmi" dεm we dεn kכl kεnsar sεl dεm.
Naw, dɛn kin yuz dis tritmɛnt fɔ trit wan kayn bɔdi kansa we dɛn kɔl ``Triple-negative breast cancer'', we at fɔ trit, i gɛt bɔku risk fɔ kam bak, ɛn i dɔn spre to ɔda pat dɛn na di bɔdi (metastatic). Risach de go bifo bak fɔ si aw dis tritmɛnt de wok fayn fɔ ``HER2-positiv'' ɛn ``ER-positiv'' brɛst kansa.
Aw dis tritmɛnt kin wok?
Tink bɔt wi bɔdi in imyun sistɛm lɛk ami we de protɛkt wan kɔntri. Dis ami de luk fɔ ɛn pwɛl ɛnimi dɛn ɔltɛm lɛk jem ɛn vayrɔs dɛn we de kam insay di bɔdi. Bɔt, kansa sɛl dɛn na ɛnimi dɛn we rili kɔni. Sɔntɛnde, dɛn kansa sɛl ya kin mek lɛk se dɛn na difrɛn we dɛn fɔ mek wi ami nɔ kech dɛn. Lɛk ɛnimi spay.
Na dis na wetin imyunotɛrapi de du:
1. Fɔ ɛp fɔ no di ɛnimi: Sɔm imyunotɛrapi drɔgs dɛn de pul di kansa sɛl dɛn, we de sho klia wan se wi imyun sistɛm se "na di ɛnimi de ya."
2. Fɔ mek di ami strɔng: Ɔda kayn drɔgs de wok bay we dɛn de mek di sɛl dɛn (sojaman dɛn) na wi imyun sistɛm strɔng, we de gi dɛn mɔ pawa fɔ fɛt di kansa sɛl dɛn.
Tu men we dɛn de fɔ du dis:
- Aktiv Imyun Tεrapi: Dis involv fכ stכdi spεshal mak dεm (antijen) pan yu brεst kεnsar sεl dεm εn tren yu imyun sistεm fכ atak כnli dεn mak dεm de.
- Passive Immunotherapy: Insay dis, dɛn kin gi spɛshal mɛrɛsin dɛn we dɛn mek na lɛbɔtri fɔ mek di bɔdi ebul fɔ fɛt kansa we i dɔn gɛt.
Wetin na di imyunotɛrapi mɛrɛsin dɛm wae dɛn kin yuse fɔ brɔst kansa?
Naw, tu men imyunotɛrapi mɛrɛsin dɛn de we dɛn dɔn gri fɔ fɔ mek pɔsin gɛt bɔdi kansa.
1. Pɛmbrolizumab (Keytruda®): we dɛn kɔl Pɛmbrolizumab:dis dכg dεn de yuz fכ `(Triple-negative brεst kεnsar)`. Dis drɔg de blok wan prɔtin we di kansa sɛl dɛn de yuz fɔ ayd frɔm di imyun sistɛm. Dis kin mek am izi fɔ di imyun sistɛm fɔ no di kansa sɛl dɛn. Sɔntɛnde, dɛn kin gi dis mɛrɛsin bifo ɛn afta di ɔpreshɔn fɔ mek di kansa nɔ kam bak. dis dכg dεn de yuz am bak fכ kεnsar dεm we dεn spre to כda pat dεm na di bכdi, if sכm ``Biomarkers`` de na di DNA fכ di kεnsar tכmכro.
2. Dostarlimab (Jemperli®): Dɛn kin yuz dis mɛrɛsin fɔ brɔst kansa we dɔn kam bak afta ɔda tritmɛnt ɛn we gɛt wan patikyula tumbu mak.
Di impɔtant tin na dat nɔto ɔl dɛn mɛrɛsin ya fayn fɔ ɔlman we sik. Na yu dɔktɔ nɔmɔ go ebul fɔ no if dis tritmɛnt rayt fɔ yu, bay di kayn, stej, ɛn di prɛzɛns fɔ sɔm patikyula bayomak dɛn na yu kansa.
Aw dɛn kin gi imyunotɛrapi?
dis tritmεnt dεn kin gi am lεk salin sכlushכn tru wan vein (intravenכs - IV). De tritmɛnt plan kin difrɛn difrɛn wan fɔ yu kɔndishɔn. Bɔt bɔku pipul dɛn kin gɛt dis tritmɛnt ɛvri 3 to 6 wik . Sɔntɛnde, dɛn kin nid fɔ kɔntinyu fɔ du dis tritmɛnt fɔ sɔm mɔnt to tu ia.
Lɛ wi lan bak bɔt di bad tin dɛn we kin apin to wi.
Lɛk ɛni tritmɛnt fɔ kansa, imyunotɛrapi kin mek yu gɛt sayd ɛfɛkt. Bɔt dɛn nɔ de afɛkt ɔlman di sem we. Sɔm pipul dɛn kin gɛt smɔl prɔblɛm, ɛn ɔda pipul dɛn nɔ kin fil natin atɔl. Di tin we impɔtant pas ɔl na fɔ tɛl yu dɔktɔ bɔt ɛnitin we nɔ fayn fɔ yu kwik kwik wan.
Lɛ wi tek wan luk pan wetin na di kɔmɔn ɛn siriɔs sayd ɛfɛkt dɛm.
| Tayp fɔ di sayd ɛfɛkt | Tin dɛn we wi fɔ ɛkspɛkt |
|---|---|
| Kɔmɔn sayd ɛfɛkt dɛn |
|
| Rarely siriɔs sayd ɛfɛkt dɛn |
|
Nɔ fred fɔ dɛn sayd ɛfɛkt ya. Yu dɔktɔ ɛn di mɛdikal tim de wach dɛn ɔltɛm. Dɛn go gi yu bak di mɛrɛsin ɛn advays we yu nid fɔ kɔntrol dɛn sayd ɛfɛkt ya.
Aw dis tritmɛnt kin wok fayn?
Immunotherapy na wan pan di nyu ɛn prɔmis tritmɛnt dɛm fɔ di fild fɔ tritmɛnt fɔ kansa. Na mɔtalman, i dɔn ɛp fɔ mek di pipul dɛn we gɛt kansa we nɔ bin izi fɔ trit trade, lɛk triplɛ-nɛgitiv bɔdi kansa, liv lɔng ɛn lɔng.
Wan big stɔdi sho se di wan dɛn we bin gɛt di imyunotɛrapi drɔg we dɛn kɔl Pembrolizumab wit di kemotɛrapi bin liv lɔng pas di wan dɛn we bin gɛt di kemotɛrapi nɔmɔ.
Bɔku bɔku stɔdi dɛn dɔn ɔlrɛdi de ɔlsay na di wɔl fɔ chɛk aw imyunotɛrapi de wok fayn fɔ difrɛn kayn bɔdi kansa. Dis dɔn mek dis fil de go bifo ɛvride.
Mɛsej we dɛn kin kɛr go na os
- Immunotherapy nɔto mɛrɛsin we de kil kansa sɛl dɛn lɛk kemotɛrapi. I de wok bay we i de mek yu yon imyun sistɛm fɔ ɛp fɔ fɛt kansa.
- dis na rili imכtant tritmεnt, spεshal fכ `(Triple-negative breast cancer)`.
- Lɛk ɔl tritmɛnt, sɔm kayn bad bad tin kin apin to yu, bɔt yu kin ebul fɔ kɔntrol am , so nɔr fred fɔ tɔk to yu dɔktɔ bɔt ɛnitin we yu nɔr kin fil fayn.
- Immunotherapy na big op fɔ mɛn kansa.Dɛn stil de du risach bɔt dis, ɛn i pɔsibul se bɔku ɔda pipul dɛn go bɛnifit frɔm dis tumara bambay.
- Di bɛst we fɔ no if dis tritmɛnt fayn fɔ yu na fɔ tɔk to yu dɔktɔ we de mɛn yu kansa. Dɛn go ebul fɔ ansa ɔl yu kwɛstyɔn dɛn.
💬 Comments (0)
No kɔmɛnt nɔ de yet. Ad yu kɔmɛnt ya fɔ di fɔs tɛm.
Ad yu kɔmɛnt